10:00 am EST
Join us for a virtual event featuring the Department of Pathology's Dr. Celina Kleer, who will host a discussion related to her experiences in understanding breast cancer and her journey as a physician-scientist.
Dr. Celina Kleer named 2019 AACR Outstanding Investigator in Breast Cancer Research
Along with co-investigators, Sabra Djomehri, a graduate student in Celina Kleer's Laboratory, has discovered the proteomic landscape of metaplastic carcinomas, the most aggressive type of triple negative breast cancer. The study, published in [...]
The American Association for Cancer Research announced that Celina Kleer, MD, the Harold A. Oberman Collegiate Professor of Pathology and Director of the Breast Pathology Program, will be the recipient of the 2019 Outstanding Investigator in Breast Cancer Research, supported by the Breast Cancer Research Foundation.
Cancer biologists and engineers collaborated on a device that could help predict the likelihood of breast cancer metastasis.
Congratulations to Dr. Celina Kleer, the Harold A. Oberman Collegiate Professor of Pathology, who has been selected as the 2018 recipient of the 7th Annual MICHR Distinguished Clinical and Translational Research Mentor Award!
Dr. Kleer was nominated by her trainees as well as peers at U-M Medical [...]
Talha Anwar is in the Medical Scientist Training Program (MSTP) and the Molecular and Cellular Pathology Program at U-M. He defended his PhD thesis, Regulation of EZH2 in triple-negative breast cancer, on Friday April 6, 2018 [...]
The laboratory of Dr. Celina Kleer, Harold A. Oberman Collegiate Professor, isolated human mesenchymal stem cells from breast cancer metastasis. The lab discovered that a collagen receptor tyrosine kinase, DDR2, mediates stromal-cancer communication and induces breast cancer metastasis. The study provides the basis for the development of DDR2 inhibitors. The article appeared in Cell Reports and can be found at www.cell.com.
The laboratory of Dr. Celina Kleer, Harold A. Oberman Collegiate Professor, discovered that mammary-specific knock down of CCN6 results in mammary carcinomas with features of human metaplastic carcinomas. This model may lead to discovery of new diagnostic and therapeutic targets for this rare and aggressive form of triple negative breast cancer. The article appeared in Oncogene, on the November 7th 2016 issue, and can be found at www.nature.com